Physician profile
Gina C Laughlin
NPI 1922363845
$1,856.07
in general payments reported to CMS, 2019-2025
21 companies · $815 in 2025
The $815 reported for 2025 was more than what 82% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $74.28 · 2023: $311 · 2024: $656 · 2025: $815.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,782.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,781.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $491.67 | 2023-2025 | |
| Lilly USA, LLC | $290.48 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Novo Nordisk INC | $287.59 | 2022-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $185.68 | 2023-2025 | |
| Exact Sciences Corporation | $92.95 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $61.34 | 2023-2025 | Trelegy Ellipta |
| Astellas Pharma US INC | $55.42 | 2024-2025 | Veozah |
| Sumitomo Pharma America, INC. | $41.27 | 2024-2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $39.51 | 2023-2024 | Gardasil, Gardasil 9, Capvaxive |
| Medtronic, INC. | $39.36 | 2024 | Minimed 780g |
| Biohaven Pharmaceutical Holding Company LTD. | $33.54 | 2022 | |
| Axsome Therapeutics, INC. | $32.40 | 2025 | Auvelity |
| Phathom Pharmaceuticals, INC. | $30.93 | 2024-2025 | Voquezna |
| Vanda Pharmaceuticals INC. | $30.52 | 2024 | Fanapt, Hetlioz |
| Abiomed | $29.33 | 2024 | Impella |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $28.02 | 2024 | Quviviq |
| Alnylam Pharmaceuticals INC. | $27.18 | 2025 | Givlaari |
| Dynavax Technologies Corporation | $15.82 | 2025 | Heplisav-B |
| Bayer Healthcare Pharmaceuticals INC. | $14.95 | 2025 | |
| Azurity Pharmaceuticals, INC. | $14.45 | 2023 | Edarbi |
| Amgen INC. | $13.66 | 2023 | Repatha, Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gina Laughlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.